CClinicalTrials.gg
Status unknownNCT05416073TACE-HAICUpdated Feb 24, 2023

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

A Phase 4 interventional study of Esketamine and Sufentanil in Hepatocellular Carcinoma, Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating spinal cord NMDA receptor(N-methyl-D-aspartic acid receptor). The investigators speculate that this may be the same as the mechanism of severe abdominal pain caused by HAIC(Hepatic Artery Infusion Chemotherapy) during oxaliplatin infusion. The analgesic effect of Esketamine is mainly related to its inhibition of NMDA receptor in spinal cord. Therefore, this study hypothesized that Esketamine can inhibit the sensitization of spinal cord center by inhibiting NMDA receptor, so as to alleviate severe abdominal pain during HAIC perfusion, and reduce abdominal pain caused by ischemia and inflammation by TACE(transcatheter arterial chemoembolization) by improving organ perfusion and anti-inflammatory effect, Therefore, it is expected that Esketamine can better alleviate acute severe abdominal pain caused by TACE-HAIC (transcatheter arterial chemoembolization combined with Hepatic Artery Infusion Chemotherapy )treatment than sufentanil, decrease the dosage of opioids, and reduce the incidence and degree of chronic abdominal pain after treatment.

02

Conditions studied

  • Hepatocellular Carcinoma
  • Transarterial Chemoembolization
  • Hepatic Arterial Infusion Chemotherapy
  • Pain
03

In context

Carcinoma

6,738 studies on the registry are indexed under Carcinoma; 1,159 are open to participants now.

This study's planned enrollment of 70 is above the median of 45 across 5,167 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

The Second Affiliated Hospital of Chongqing Medical University is the lead sponsor of 98 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participate in this study and sign informed consent
  • Voluntarily receive postoperative intravenous controlled analgesia
  • Patients receiving TACE-HAIC treatment
  • HCC (hepatocellular carcinoma)patients with primary liver cancer BCLC(Barcelona Clinic Liver Cancer) stage B and C, liver function A
  • Age 18 to 80

Exclusion criteria

Exclusion Criteria:

  • Patients who were unable to cooperate or refused to participate in the trial
  • Pregnant women
  • Patients with sensory abnormalities such as diabetes neuropathy
  • Patients with or having a history of serious mental disorders
  • Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic / diastolic blood pressure more than 180/100mg)
  • Patients with unstable angina pectoris or myocardial infarction within 6 months or congestive heart failure
  • Patients with intracranial hypertension or glaucoma
  • Patients with hyperthyroidism without treatment or insufficient treatment
  • Patients with severe respiratory dysfunction
  • Allergy or existing contraindication to chemotherapeutic drugs, opioids or ketamine drugs
  • Can not follow with the study procedure
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Esketamine-PCIA(patient controlled intravenous analgesia)

    PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.

    Drug: Esketamine

  • Active comparator
    Sufentanil-PCIA(patient controlled intravenous analgesia)

    PCIA formula:100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.

    Drug: Sufentanil

Interventions

  • DrugEsketamine

    PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.

    Also known as: patient controlled intravenous analgesia

  • DrugSufentanil

    PCIA formula:100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.

    Also known as: patient controlled intravenous analgesia

06

What researchers measure

Primary outcomes

  1. Maximum pain intensity in the first 3 hours of HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From the beginning of HAIC treatment to 3 hours after HAIC treatment

  2. Pain intensity at 1 hour after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From the beginning of HAIC treatment to 1 hour after HAIC treatment

  3. Pain intensity at 2 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 1 hour to 2 hours after HAIC treatment

  4. Pain intensity at 3 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 2 hours to 3 hours after HAIC treatment

Secondary outcomes

  1. Numbers of analgesic pump compressions

    When the patients felt pain, the patient controlled analgesia pump can be pressed once

    Time frame: From the beginning of HAIC treatment to 48 hours after HAIC treatment

  2. Analgesic consumption

    Analgesic consumption is assessed by the total amount of pain remedy with dolantin when the analgesic effect is poor after pressing analgesic pump for 3 times or more

    Time frame: From the beginning of HAIC treatment to 48 hours after HAIC treatment

  3. Pain intensity at 8 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 7 hours to 8 hours after HAIC treatment

  4. Pain intensity at 16 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 15 hours to 16 hours after HAIC treatment

  5. Pain intensity at 24 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 23 hours to 24 hours after HAIC treatment

  6. Pain intensity at 32 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 31 hours to 32 hours after HAIC treatment

  7. Pain intensity at 40 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 39 hours to 40 hours after HAIC treatment

  8. Pain intensity at 48 hours after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 47 hours to 48 hours after HAIC treatment

  9. Pain intensity on the seventh days after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 7 days to 8 days after HAIC treatment

  10. Pain intensity On the 14th day after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 13 days to 14 days after HAIC treatment

  11. Pain intensity on the 21st after HAIC treatment

    Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

    Time frame: From 20 days to 21 days after HAIC treatment

Other outcomes

  1. Ramsay Sedation score at 1 hour after HAIC treatment

    Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.

    Time frame: From the beginning of HAIC treatment to 1 hour after HAIC treatment

  2. Ramsay Sedation score at 2 hours after HAIC treatment

    Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.

    Time frame: From 1 hour to 2 hours after HAIC treatment

  3. Ramsay Sedation score at 3 hours after HAIC treatment

    Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.

    Time frame: From 2 hours to 3 hours after HAIC treatment

  4. Ramsay Sedation score at 8 hours after HAIC treatment

    Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.

    Time frame: From 7 hours to 8 hours after HAIC treatment

  5. The quality of sleep on the fist day after HAIC treatment

    The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0\~25 points indicate poor sleep quality;76\~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)

    Time frame: From the ending of HAIC treatment to 1 day after HAIC treatment

  6. The quality of sleep on the second day after HAIC treatment

    The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0\~25 points indicate poor sleep quality;76\~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)

    Time frame: From 1 day to 2 days after HAIC treatment

  7. The quality of sleep on the third day after HAIC treatment

    The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0\~25 points indicate poor sleep quality;76\~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)

    Time frame: From 2 days to 3 days after HAIC treatment

  8. Adverse reaction

    Adverse reaction is recorded according to follow-up visits after HAIC treatment

    Time frame: From the beginning of HAIC treatment to 72 hours after HAIC treatment

  9. Degree of satisfaction

    Degree of satisfaction is assessed by patient using numerical rating scale (0-10, 0 represents unsatisfactory; 10 represents complete satisfaction;higher scores mean a better outcome)

    Time frame: From the beginning of HAIC treatment to 24 hours after HAIC treatment

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital, Chongqing Medical University
    Chongqing, Chongqing 400010, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The individual participant data for this study is available from the sponsor on reasonable request through email.

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416073
Lead sponsor
The Second Affiliated Hospital of Chongqing Medical University
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Jun 22, 2022
Primary completion
Apr 30, 2023 (estimated)
Completion
Apr 30, 2023 (estimated)
Last update
Feb 24, 2023

Study contacts

Duan Guang you, MD
Contact
duangy@hospital.cqmu.edu.cn
18323376014 ext. +86
wang Da gang, MD
Contact
kuanrenlunli@qq.com
023 63693014 ext. +86
Huang He, MD
study chair · The Second Affiliated Hospital, Chongqing Medical University
Huang yan, MD
principal investigator · The Second Affiliated Hospital, Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion